Pharmacologic management in functional neurological disorder is guided by a different logic than in many primary neurological diseases. Because functional symptoms arise from altered brain network functioning rather than structural damage, medication is rarely curative on its own and is usually an adjunct to education, rehabilitation, and psychotherapy. The central principle is to target co‑occurring conditions—such as anxiety, depression, chronic pain, insomnia, and migraines—that amplify or perpetuate functional symptoms, while avoiding treatments that reinforce disability, passivity, or illness-focused behaviors. This requires careful assessment of the person’s symptom patterns, psychological context, and goals, as well as transparent discussion that the role of medication is supportive rather than definitive.
When considering any medication in this setting, clinicians must weigh the quality of evidence very explicitly. Most randomized controlled trials in functional neurological disorder are limited, and many pharmacologic decisions rely on extrapolation from broader psychiatry or pain literature. For example, data supporting the use of an SSRI or SNRI often come from studies on major depressive disorder, generalized anxiety, or chronic pain syndromes rather than FND-specific trials. Accordingly, medications are chosen based on the best match between their proven indications and the individual’s comorbidities, with an understanding that improvement in mood, arousal, or pain processing can indirectly reduce the intensity and frequency of functional symptoms. Patients should be told clearly what is and is not known so that expectations remain realistic and collaborative.
An important mechanistic principle is that functional symptoms often reflect dysregulation in attention, prediction, and threat systems. Medications that reduce threat sensitivity, stabilize mood, or improve sleep can help recalibrate these systems, but only in concert with behavioral change. For instance, reducing hyperarousal via an SSRI may make it easier for a patient to engage with physiotherapy, graded exposure, or trauma-focused work. Conversely, sedating drugs that blunt attention or motivation without addressing underlying processes may impede learning and plasticity. Clinicians therefore favor agents that support engagement, learning, and activity, and avoid those that foster sedation, passivity, or avoidance as the dominant coping strategy.
Another guiding concept is starting low and going slow, with frequent reassessment. Individuals with functional neurological disorder are often highly sensitive to bodily sensations and may interpret minor physiological changes as threatening. This interoceptive sensitivity can make them more prone to noticing and worrying about side effects, which in turn can exacerbate symptoms. Beginning with low doses, titrating cautiously, and normalizing transient physical sensations reduces the risk of early discontinuation. Written plans and explicit timelines for dose changes, trial periods, and follow-up appointments help maintain a sense of structure and safety around pharmacologic trials.
Clear communication about the rationale for any medication is essential to avoid reinforcing misattributions. If a drug is prescribed primarily to treat co‑occurring depression or anxiety, that purpose should be communicated as such, not framed as directly “fixing the nerves” or “controlling seizures.” Linking the medication to specific, functional goals—such as having enough emotional stability to participate in therapy or enough pain relief to tolerate graded physical activity—helps patients understand that the drug is one component of a broader recovery plan. This framing promotes active self-management rather than a passive belief that the solution lies purely in pharmacology.
Because functional disorders frequently coexist with complex psychosocial stressors, polypharmacy is a persistent risk. A core principle is to prescribe as few medications as clinically necessary, each with a clear target symptom and measurable outcome. Before adding a new agent, clinicians should re-evaluate existing prescriptions to see whether they can be simplified, tapered, or replaced. Regular medication reviews—looking for duplicative actions, cumulative side effects, and agents no longer needed—are important to prevent escalating complexity that can overshadow rehabilitation efforts and complicate diagnostic clarity.
Choice of class and agent should consider not only efficacy but also the overall pattern of the person’s symptoms. For someone with prominent anxiety and insomnia who also has functional motor symptoms, a non-sedating SSRI with a low burden of cognitive side effects may be preferable to medications that cause drowsiness or balance impairment. Similarly, for patients with co‑occurring chronic pain, an SNRI with evidence in neuropathic or musculoskeletal pain may be chosen to target both mood and pain modulation. In each case, somatic symptom amplification and fall risk must be considered, as functional motor and gait problems can be worsened by medications that impair alertness, coordination, or blood pressure regulation.
Short-acting and dependency-prone medications, such as benzodiazepines and certain sedative-hypnotics, occupy a special place in pharmacologic planning for functional neurological disorder. While they can quickly reduce acute anxiety or insomnia, they also risk reinforcing the notion that only immediate, external relief is effective, undermining long-term coping strategies. They can also produce withdrawal phenomena and rebound symptoms that may be misinterpreted as a worsening of the underlying functional condition. As a result, these agents, if used at all, are generally limited to very short courses, well-defined acute situations, or as temporary bridges to more sustainable treatments, with clear exit strategies discussed from the outset.
Monitoring and documenting responses to treatment must be systematic rather than impressionistic. Because symptoms in FND can fluctuate markedly from day to day, isolated experiences of improvement or deterioration should not alone dictate medication changes. Structured symptom diaries, standardized rating scales for mood or anxiety, and functional markers such as time spent walking, working, or engaging socially are useful to gauge whether a medication is genuinely beneficial. These objective or semi-objective anchors help distinguish true drug response from the natural variability of the condition or from contextual influences such as stress, sleep disruption, or life events.
A final overarching principle is ongoing education and shared decision-making. People with functional neurological disorder frequently have a history of feeling dismissed or over-medicalized, with prior experiences of either being denied treatment or being prescribed multiple medications without clear explanation. Engaging them as partners—discussing options, uncertainties in the evidence, and personal preferences—builds trust and improves adherence. This collaborative approach makes it easier to adjust or discontinue medications when appropriate, refine the regimen over time, and keep pharmacologic strategies aligned with evolving rehabilitation and psychotherapy goals.
Antidepressants and anxiolytics: indications and limitations
In people with functional neurological disorder, antidepressants are most often used to treat co‑occurring mood and anxiety disorders rather than the functional symptoms themselves. Major depressive disorder, generalized anxiety disorder, panic disorder, post‑traumatic stress disorder, and obsessive–compulsive disorder are all more common in this population than in the general public. When these conditions remain untreated, they can heighten arousal, increase catastrophic thinking, and lower frustration tolerance, all of which can worsen functional symptoms or make it harder to engage with rehabilitation. Prescribing an SSRI or SNRI is therefore usually framed as treating a clearly defined depressive or anxiety disorder, supported by robust evidence from psychiatric trials, with the expectation that improved mood and reduced anxiety will indirectly decrease functional symptom intensity.
Selective serotonin reuptake inhibitors such as sertraline, escitalopram, fluoxetine, and citalopram are typically considered first‑line. They have a well‑established safety profile, are non‑sedating at therapeutic doses, and generally do not impair coordination or cognition, an important consideration for individuals with functional motor symptoms or dissociative seizures. In clinical practice, response is often gradual, with benefits emerging over weeks rather than days. This time course must be explained clearly to avoid the expectation of rapid symptom elimination and to reduce the risk that early, nonspecific physical sensations are misattributed to harm from the medication. For example, transient nausea, mild headache, or a brief increase in anxiety during the first one to two weeks can be normalized as predictable side effects that typically fade, while emphasizing ongoing monitoring and the option to adjust the dose if they persist or become intolerable.
Serotonin–norepinephrine reuptake inhibitors such as venlafaxine and duloxetine are considered when there is co‑occurring chronic pain, neuropathic symptoms, or when an SSRI has been ineffective or poorly tolerated. Their dual action on serotonin and norepinephrine can be advantageous for patients whose symptom profile includes significant fatigue, pain amplification, or concentration difficulties related to depression or anxiety. Duloxetine, for instance, has evidence for neuropathic and musculoskeletal pain syndromes, which may overlap with the pain experiences of some individuals with functional neurological disorder. However, these medications can also cause dose‑related increases in blood pressure, vivid dreams, or agitation, so close follow‑up is important to ensure that potential benefits outweigh emerging side effects and that new sensations do not provoke further health anxiety.
Other antidepressants have more specialized roles. Mirtazapine may be useful when insomnia, weight loss, or poor appetite are prominent, given its sedating and appetite‑stimulating properties at lower doses. It can help reset sleep–wake cycles that are disrupted by chronic hyperarousal, but the associated daytime sedation and weight gain need to be discussed upfront, especially for those already struggling with fatigue or body‑image concerns. Bupropion may be considered for low‑energy depression when anxiety is not predominant, as it tends to be more activating and has a lower risk of sexual side effects. However, because bupropion can lower seizure threshold, it is typically avoided or used very cautiously in people with functional seizures until structural epilepsy has been confidently excluded and the patient’s overall risk profile is clearly understood.
The decision to start an antidepressant should be based on a structured assessment rather than on the mere presence of distress or tearfulness in the clinic. Diagnostic interviews, validated screening tools (such as PHQ‑9 or GAD‑7), and a careful history help distinguish between understandable emotional responses to illness, subclinical symptoms, and full‑threshold mood or anxiety disorders. This distinction matters because inappropriate medicalization of normal emotional reactions can reinforce a sense of fragility and undermine psychological interventions that focus on coping and resilience. When the threshold for a pharmacologic trial is met, it is useful to define specific target symptoms—such as panic attacks, persistent low mood, intrusive trauma memories, or insomnia—and to identify objective markers of improvement like increased activity, improved social participation, or greater tolerance of physiotherapy.
Setting expectations at the outset is crucial. Antidepressants should be presented as tools that can lower the “background noise” of anxiety or depression, creating a more favorable internal environment for learning new skills and participating in rehabilitation. They are not positioned as medications that directly “turn off” functional seizures or restore movement. Framing the purpose this way helps prevent disappointed expectations and discourages passive waiting for a drug to do all the work. It also makes it easier to later taper or discontinue the medication once mood and anxiety have stabilized and the person is functioning better. Collaborative planning might include a timeline for reassessment after 8–12 weeks at a therapeutic dose, with a shared understanding that lack of meaningful improvement in that period warrants re‑evaluation of diagnosis, dose, adherence, or the need to prioritize psychotherapeutic approaches.
Anxiolytic strategies are similarly oriented toward treating specific anxiety disorders or debilitating hyperarousal, with an emphasis on non‑sedating and non‑addictive medications. SSRIs and SNRIs remain first‑line for chronic anxiety conditions, but short‑term use of adjunctive agents may be considered. For example, hydroxyzine can be used intermittently for acute spikes of anxiety or insomnia, though its anticholinergic properties and sedating effects require attention in those with balance problems or cognitive vulnerabilities. Beta‑blockers such as propranolol may reduce the physical expression of performance or situational anxiety—tremor, palpitations, flushing—but must be titrated carefully in patients with dysautonomia, postural symptoms, or baseline low blood pressure, which are not uncommon in FND and can be easily mistaken for worsening neurological symptoms.
Benzodiazepines occupy a particularly delicate position in the management of functional neurological disorder. While they can provide rapid relief in acute panic, severe agitation, or short‑term crisis situations (for example, during an inpatient admission when a patient is overwhelmed by new functional symptoms), their use beyond brief, time‑limited indications carries substantial risks. Tolerance, psychological and physiological dependence, and withdrawal syndromes are well documented, and these phenomena may be easily misinterpreted by patients and clinicians as unpredictable fluctuations of the underlying functional condition. Furthermore, their sedating and amnestic properties can impair engagement in psychotherapy and physiotherapy, blunt the learning of new coping strategies, and reduce motivation for graded exposure or activity. For these reasons, if benzodiazepines are used at all, clear boundaries are essential: lowest effective dose, a defined duration, explicit review dates, and a parallel plan to transition to non‑benzodiazepine treatments and behavioral strategies.
Non‑benzodiazepine anxiolytics such as buspirone are sometimes considered for generalized anxiety when avoidance of sedation and dependence is a high priority. Buspirone’s onset of action is gradual and its effect size more modest compared to benzodiazepines, which makes it less suitable for acute crises but potentially useful for chronic worry and hypervigilance. As with antidepressants, patients should be informed that benefits may take several weeks to become apparent and that persistence, in conjunction with cognitive‑behavioral techniques, usually yields better outcomes than frequent early medication changes. The need for multiple daily dosing can be a practical barrier, so aligning the schedule with existing routines and using reminders can help with adherence.
An important limitation of both antidepressants and anxiolytics in functional neurological disorder is the risk of diagnostic overshadowing. When a mood or anxiety‑targeting medication is prescribed, there can be a subtle shift toward attributing ongoing functional symptoms entirely to psychiatric illness, especially if the clinician’s understanding of FND is incomplete. This can lead to unnecessary dose escalation, frequent changes of SSRI or SNRI without adequate trial periods, or addition of multiple agents in an attempt to chase fluctuating symptoms. Such approaches increase the burden of side effects, complicate the clinical picture, and may reinforce the patient’s belief that they have an intractable, biologically severe illness. To avoid this, clinicians must repeatedly return to a biopsychosocial formulation, explaining that changes in functional symptoms are influenced by attention, beliefs, stress, and behavior as well as by neurochemistry, and that medication is only one part of a broader strategy.
Another limitation is that individuals with functional neurological disorder often exhibit heightened sensitivity to bodily sensations and may report a broad range of adverse experiences with psychotropic medications. This does not mean that the medication is contraindicated, but that careful titration, reassurance, and validation are vital. For instance, rather than dismissing reported side effects as “all in your head,” a clinician might acknowledge that some people with FND are more aware of subtle changes in heart rate, gut motility, or sleep, then collaboratively distinguish benign, time‑limited sensations from concerning reactions that warrant dose adjustment or discontinuation. Written information, safety‑net advice, and accessible follow‑up contact reduce the likelihood that emerging, usually mild physical changes trigger emergency visits or abrupt self‑discontinuation.
Practical strategies can help optimize outcomes. Starting at half the usual initial dose and increasing slowly minimizes early adverse reactions and builds confidence. Scheduling a specific check‑in within two to four weeks reinforces that the medication trial is supervised and modifiable. Using simple rating scales or brief symptom diaries allows the person to see trends in mood, anxiety, sleep, and activity over time rather than focusing on day‑to‑day fluctuations. Integrating psychoeducation—for example, explaining how SSRIs gradually adjust serotonin signaling and reduce limbic overreactivity—can counter catastrophic interpretations of transient side effects and foster a sense of collaboration rather than experimentation done “to” the patient.
The decision to maintain, adjust, or stop antidepressants or anxiolytics should always be situated within the broader trajectory of rehabilitation and psychotherapy. If a person is actively engaging in physiotherapy, occupational therapy, or trauma‑focused work and is experiencing progressive functional gains, stable low‑dose medication may be continued for a defined maintenance period to consolidate improvement. If, on the other hand, functional symptoms remain static despite adequate pharmacologic treatment of mood and anxiety, the focus should shift to revisiting the formulation, addressing barriers to behavioral change, and intensifying non‑pharmacologic interventions rather than indefinitely escalating doses. Planned, gradual tapers after a sustained period of stability can be framed as a sign of recovery and autonomy, with clear instructions on how to respond if withdrawal‑like sensations or mood fluctuations occur, thereby reinforcing self‑efficacy and reducing long‑term dependence on medication as the centerpiece of care.
Managing pain, fatigue, and sleep disturbances in fnd
Pain in functional neurological disorder is rarely explained by structural damage alone and often overlaps with central sensitization, muscle tension, migraines, and co‑occurring conditions such as fibromyalgia or irritable bowel syndrome. Rather than searching indefinitely for a single lesion to “explain” the pain, treatment focuses on reducing nervous system sensitivity and improving function. Education that pain is real but not necessarily a sign of ongoing harm, along with reassurance that movement is generally safe, is foundational before any medication is considered. Without that groundwork, even well‑chosen drugs can be interpreted as proof of severe disease or failure, reinforcing avoidance and disability.
First‑line pharmacologic strategies for chronic pain in this context typically borrow from the broader chronic pain and neuropathic pain literature, where the evidence base is stronger than in FND‑specific studies. SNRIs such as duloxetine or venlafaxine and certain tricyclic antidepressants like amitriptyline or nortriptyline may be considered when there is significant neuropathic, musculoskeletal, or widespread pain. These agents are not painkillers in the traditional sense but modulators of pain processing pathways, and benefits are usually gradual rather than immediate. Before prescribing, clinicians should clarify that the goal is to make pain more manageable to allow graded activity and physiotherapy, not to eliminate all discomfort. Emphasizing this purpose prevents a cycle of increasing doses or drug changes driven by the unrealistic expectation of complete pain relief.
Dosing strategies need to be conservative, especially because many people with functional neurological disorder are highly attuned to bodily sensations and to side effects. Starting at low doses—for example, low‑dose amitriptyline at bedtime or duloxetine below standard pain doses—and titrating slowly can improve tolerability. Patients are advised that common, time‑limited effects such as dry mouth, mild dizziness, transient nausea, or early morning grogginess are expected during the first one to two weeks and often dissipate. Normalizing these experiences and providing clear parameters for when to contact the prescriber (e.g., severe palpitations, rash, sudden mood changes) reduces anxiety about every new sensation and decreases abrupt discontinuation after only a few doses.
In some cases, anticonvulsant agents such as gabapentin or pregabalin are trialed for neuropathic‑type symptoms, but caution is required. These medications can cause sedation, weight gain, and cognitive slowing, which may interfere with participation in rehabilitation, increase fall risk, or be misinterpreted as worsening neurological symptoms. When used, they should have a clear indication, specific functional goals, and predefined criteria for continuation or tapering. Repeated dose escalations to chase fluctuating pain without demonstrable functional benefit should be avoided, as they contribute to polypharmacy and may overshadow non‑pharmacological approaches that are central to long‑term improvement.
Opioids are generally discouraged in functional neurological disorder, especially for chronic non‑cancer pain. Short courses may occasionally be used for acute, clearly defined nociceptive pain with an identifiable time‑limited cause, but long‑term prescribing can worsen pain sensitivity, impair mood, and reinforce passivity and disability behaviors. Opioid‑related side effects such as constipation, sedation, hormonal changes, and cognitive dulling can further complicate the symptom picture and feed into catastrophic interpretations of bodily sensations. When patients are already on opioids at presentation, a careful, collaborative plan to taper, combined with supportive non‑opioid pain strategies and psychological interventions, is often necessary to create a therapeutic environment conducive to recovery.
Non‑pharmacologic strategies are essential companions to any medication trial for pain. Graded physical activity, physiotherapy that explicitly addresses fear of movement, relaxation training, pacing techniques, and cognitive‑behavioral interventions that target catastrophizing and attentional bias toward pain all have important roles. The rationale for medications is best framed as reducing the “volume” of pain so that these active strategies become more achievable, rather than as a replacement for them. Regular review of function—such as walking distance, time out of bed, ability to perform household tasks—helps determine whether a drug is supporting or hindering rehabilitation, guiding decisions to continue, adjust, or taper.
Fatigue in functional neurological disorder is multifactorial and often overlaps with sleep disturbance, deconditioning, mood disorders, autonomic dysregulation, and chronic pain. A thorough assessment looks for reversible contributors such as anemia, thyroid disease, medication effects, and untreated depression or anxiety, but recognizes that in many cases no single biological explanation is sufficient. Education that fatigue is a genuine but modifiable symptom of a system under chronic stress or hyperarousal can be more helpful than exhaustive, repetitive testing that implicitly signals that something catastrophic is being missed. Emphasizing that small, consistent behavior changes can gradually improve energy counteracts the common pattern of boom‑bust activity cycles that perpetuate exhaustion.
Pharmacologic approaches to fatigue in FND are limited and should never be the primary or solitary strategy. Treating co‑existing depression or anxiety with an SSRI or SNRI can indirectly improve energy by reducing psychic and physical tension, poor sleep, and cognitive overload. When pain is a major driver of fatigue, the pain‑modulating medications outlined above may secondarily improve stamina by allowing more restorative rest and more consistent activity. Stimulant medications such as modafinil or methylphenidate are generally avoided unless there is a comorbid condition with clear evidence of benefit, such as narcolepsy or well‑characterized attention‑deficit/hyperactivity disorder, and even then, their potential to increase anxiety, palpitations, or insomnia must be weighed carefully.
Instead of focusing on stimulants, attention is directed toward structured activity management and sleep–wake regulation. Activity pacing, with planned rest breaks and gradual increments in physical and cognitive demands, prevents the extremes of overexertion and collapse that characterize many patients’ patterns. Occupational therapists can help design realistic schedules that balance energy‑draining and energy‑restoring activities. Simple strategies such as regular hydration, gentle stretching, and short, frequent movement breaks during sedentary tasks may provide more sustainable gains than any single pill, and they reinforce the message that the person can actively influence their own energy levels.
Sleep disturbances are highly prevalent in functional neurological disorder and contribute substantially to daytime fatigue, pain sensitivity, and cognitive difficulties. Insomnia may manifest as difficulty falling asleep, frequent awakenings, unrefreshing sleep, or irregular sleep–wake schedules, and is often fueled by hyperarousal, worry, nocturnal rumination, and inconsistent routines. Screening for primary sleep disorders such as sleep apnea, restless legs syndrome, or circadian rhythm disorders is essential, as treating these conditions can significantly improve daytime function. However, in many cases, insomnia is maintained by behavioral and cognitive patterns that respond best to non‑pharmacologic interventions.
Cognitive‑behavioral therapy for insomnia (CBT‑I) is the evidence‑based mainstay for chronic insomnia and should be prioritized over routine sedative prescribing whenever possible. Key components include stimulus control (reserving the bed for sleep and intimacy only), sleep restriction (consolidating sleep by limiting time in bed initially), relaxation training, and cognitive work targeting catastrophic thoughts about sleep. Brief, structured CBT‑I can often be integrated into broader psychological treatment for FND, and digital or group formats may be accessible when individual therapy is limited. Framing CBT‑I as a skill‑building intervention that permanently alters sleep patterns, rather than a short‑term patch, helps patients invest the necessary effort even when progress is gradual.
When medications are used for sleep, they are ideally time‑limited and adjunctive to behavioral changes. Low‑dose sedating antidepressants like amitriptyline, doxepin, or mirtazapine may be considered when insomnia coexists with depression, anxiety, or chronic pain, offering dual benefits. However, the risks of daytime sedation, weight gain, anticholinergic side effects, and impaired balance must be discussed openly, especially in those with functional gait or motor symptoms where falls are a concern. Intermittent use of antihistaminergic agents such as hydroxyzine can help acute situational insomnia, but tolerance and residual grogginess can develop, and they should not become nightly, indefinite fixtures.
Benzodiazepines and “Z‑drugs” (such as zolpidem, zopiclone, or eszopiclone) warrant particular caution. Although they can produce rapid sleep onset, regular use carries a high risk of tolerance, dependence, and rebound insomnia when doses are missed or reduced. In FND, these withdrawal and rebound phenomena can be misinterpreted as deterioration of the neurological condition, prompting further dose escalation or addition of other sedatives. Cognitive impairment, disinhibition, falls, and interactions with other CNS depressants further complicate recovery. If benzodiazepines or Z‑drugs are used at all, they should be restricted to very short courses for acute crises, with a clear stop date, explicit education about risks, and a parallel plan to transition to non‑pharmacologic strategies.
For individuals whose sleep disturbance is tightly linked to hyperarousal or intrusive trauma memories, addressing the underlying anxiety or post‑traumatic stress is crucial. SSRIs with evidence in PTSD or generalized anxiety disorder can reduce nighttime vigilance and nightmares over time, indirectly improving sleep continuity. In selected cases, alpha‑adrenergic blockers such as prazosin may be used for trauma‑related nightmares, though blood pressure and orthostatic symptoms must be closely monitored, particularly in those with pre‑existing dizziness or functional gait problems. Collaboration with mental health professionals experienced in trauma‑focused therapies ensures that pharmacologic approaches are nested within a broader treatment plan, not acting as stand‑alone solutions.
Throughout the management of pain, fatigue, and sleep problems in functional neurological disorder, the overarching goal is to support participation in rehabilitation and daily life, rather than to chase the complete removal of symptoms through escalating pharmacotherapy. Regular, structured reviews of all medications help identify agents that are no longer beneficial, are causing troublesome side effects, or are undermining engagement in physiotherapy, psychotherapy, or occupational therapy. Transparent discussion of the limited but evolving evidence base, shared decision‑making about continuing or tapering drugs, and consistent emphasis on active self‑management strategies foster autonomy and resilience, and reduce the risk that medications become the central focus of care at the expense of interventions that more directly address the mechanisms sustaining functional symptoms.
Medication pitfalls: dependence, side effects, and diagnostic overshadowing
Medication use in functional neurological disorder carries specific risks that can easily derail recovery if they are not anticipated and managed proactively. One of the most significant concerns is the development of psychological or physiological dependence, particularly on short‑acting agents such as benzodiazepines, Z‑drugs, and some opioid analgesics. In the context of FND, where symptoms fluctuate and distress is high, the rapid relief these drugs can provide is understandably attractive, but repeated use can reinforce a cycle in which the person feels unable to cope without immediate pharmacologic rescue. Over time, increasing doses may be needed to achieve the same effect, and attempts to cut back can trigger withdrawal or rebound symptoms—insomnia, heightened anxiety, tremor, or autonomic sensations—that may be misinterpreted as a “flare” of the neurological condition rather than a drug‑related phenomenon.
This interplay between dependence and symptom perception is particularly challenging in individuals with functional seizures or functional movement disorders. For example, someone who experiences fewer apparent seizures after receiving benzodiazepines in an emergency department may understandably conclude that this class of medication is the only effective treatment, even though the observed improvement may be related to sedation, suggestion, or the natural ebb and flow of attacks. If outpatient prescriptions are then continued indefinitely, the patient may begin to link safety and stability to the availability of the drug, making it far more difficult to engage in psychological therapy, physiotherapy, or exposure‑based strategies that encourage self‑management. Clinicians therefore need to differentiate clearly between short‑term crisis containment and long‑term management, setting explicit boundaries whenever dependency‑prone medications are used.
Physiological dependence and tolerance are not limited to benzodiazepines or opioids. Regular use of sedating antihistamines, certain muscle relaxants, or even high‑dose gabapentinoids can foster reliance and withdrawal‑like states on discontinuation, including rebound insomnia, restlessness, or amplified pain. In a population already hypervigilant to bodily changes, these sensations may feel alarming and be framed as a sign of worsening disease. To minimize this risk, clinicians should explain at the outset that many medications require gradual tapering rather than abrupt cessation, and they should provide written step‑down schedules when deprescribing. Framing dose reductions as part of a positive, planned transition toward active strategies—rather than as a punishment or withdrawal of care—can ease anxiety and promote collaboration.
Another major pitfall is the underrecognition and misinterpretation of side effects. People with functional neurological disorder are often especially sensitive to interoceptive signals: minor increases in heart rate, gastrointestinal discomfort, or dizziness can be intensely noticed, catastrophized, and quickly folded into the existing symptom narrative. When starting an SSRI, SNRI, or tricyclic antidepressant, for example, transient nausea, mild agitation, or sleep disturbance are common and generally benign, but in someone with FND they may be experienced as proof that the brain or body is “rejecting” the medication or that something serious is being overlooked. Without careful preparation, these sensations can trigger emergency care visits, rapid medication discontinuation, or repeated switches between agents before any has been given an adequate trial.
Side effects that mimic or overlap with the patient’s core functional symptoms are especially hazardous. Sedation, slowed thinking, or gait instability from benzodiazepines, antipsychotics, or high doses of tricyclics can look like progression of functional motor problems, while paresthesias or visual blurring from certain anticonvulsants may be interpreted as new neurological deficits. Orthostatic hypotension from antihypertensives, alpha‑blockers, or some antidepressants can worsen pre‑existing dizziness, leading clinicians or patients to suspect autonomic failure. To reduce confusion, prescribers should anticipate these overlaps, warn about them in advance, and document timing carefully. Linking symptom changes to dose adjustments on a timeline helps distinguish medication effects from the intrinsic variability of FND and supports more rational decisions about continuing, adjusting, or stopping a drug.
Polypharmacy amplifies the problem by creating complex, interacting side‑effect profiles that obscure what is driving any particular complaint. A person might be taking an SSRI for anxiety, a gabapentinoid for pain, a sedating antidepressant for sleep, and intermittent benzodiazepines for crises. Fatigue, cognitive dulling, and imbalance may then arise from cumulative central nervous system effects rather than from the functional disorder itself, yet both patient and clinicians may attribute them to “worsening FND.” The risk of such diagnostic confusion is higher when medication regimens have evolved gradually over years, with each new drug prescribed reactively to address a symptom spike rather than as part of a coherent plan. Regular, structured reviews of all prescriptions—ideally with the patient, a neurologist, and a primary care or psychiatry provider present—are critical to identify redundant agents, unnecessary duplications, and opportunities to simplify.
Even when evidence from broader psychiatric or pain literature justifies the use of a medication class, it does not eliminate the need for individualized risk–benefit assessment in FND. For instance, SNRIs like duloxetine may have good evidence for neuropathic pain and comorbid depression, but in someone with pronounced orthostatic symptoms, agitation, or blood pressure lability, they may exacerbate dizziness or autonomic complaints. Similarly, low‑dose amitriptyline may be effective for sleep and headache, but its anticholinergic and sedating properties can impair balance and cognition in a person with functional gait disorder. The mere presence of “evidence” for a drug’s efficacy in related conditions should never short‑circuit a thoughtful exploration of how its side‑effect profile intersects with that individual’s specific functional symptoms and recovery goals.
Diagnostic overshadowing is a subtler but equally consequential pitfall. This term refers to the tendency for clinicians to over‑attribute new or worsening physical symptoms to an existing diagnosis—in this case, FND or a comorbid psychiatric label—leading to premature closure of diagnostic reasoning. When medications are involved, overshadowing can take different forms. A patient who reports palpitations, tremor, and anxiety after starting an SSRI might be told these are “just part of your FND” without anyone checking for dose‑related activation, interactions with other stimulants, or thyroid dysfunction. Conversely, new neurological complaints may be dismissed as medication side effects without adequate consideration of other medical causes. Both errors can undermine trust and delay appropriate investigation when it is genuinely needed.
Overshadowing also arises when mood‑targeting or anxiolytic medications are repeatedly escalated in response to persistent functional symptoms, under the assumption that if the FND is not improving, the “underlying depression” must be insufficiently treated. This can result in very high doses of antidepressants, augmenting agents, or polypharmacy with several psychotropics, none of which address the specific maintaining factors of the functional symptoms such as avoidance, maladaptive beliefs, or trauma‑related responses. The person may conclude that their illness is extraordinarily severe and treatment‑resistant because “even all these powerful medications aren’t working,” reinforcing hopelessness and passivity. Clear formulation work that separates target symptoms for each medication from the core functional manifestations can counter this drift and refocus attention on rehabilitation.
Another aspect of diagnostic overshadowing emerges around emergency care. Individuals with functional seizures who present repeatedly to emergency departments may receive benzodiazepines, antiepileptic drugs, or even intensive care admissions based on the assumption that all convulsive episodes are epileptic. When FND is recognized but not well understood, staff may swing to the opposite extreme, attributing every physical complaint—including chest pain, severe headache, or focal weakness—to the “known functional disorder,” risking missed diagnoses of acute medical conditions. Developing clear crisis plans that specify when medications like benzodiazepines are appropriate and when they are not, along with criteria for further medical investigation, can reduce both overtreatment and under‑investigation.
The therapeutic relationship itself can be distorted by medication pitfalls. If the primary response to each flare or new symptom cluster is to add or change drugs, patients may come to view appointments as opportunities primarily to secure prescriptions or dose escalations, rather than to review progress, refine self‑management, and adjust rehabilitation plans. Conversely, if clinicians become wary of prescribing after witnessing problematic dependence or side effects, they may overcorrect and avoid discussing pharmacologic options altogether, which can leave patients feeling abandoned or disbelieved. A balanced approach acknowledges that medications have a legitimate, evidence‑informed role in treating comorbid conditions and symptom drivers, while maintaining that long‑term recovery hinges on behavioral, psychological, and rehabilitative work.
Mitigating these pitfalls begins with transparent, collaborative conversations before the first prescription is written. Discussing the intended role of each medication, anticipated time course of benefit, common and serious side effects, and clear stopping or tapering strategies sets expectations and frames drugs as tools rather than cures. For dependency‑prone agents, this includes explicit limits on duration and quantity, alongside an explanation of tolerance and withdrawal in non‑alarming language. Patients can be invited to participate in monitoring by keeping brief logs of symptom intensity, functional activity, and any new bodily sensations, which are then reviewed jointly to differentiate natural fluctuation from likely medication effects.
Consistent documentation and communication between members of the care team are equally important. When neurologists, psychiatrists, primary care clinicians, and therapists share a unified understanding of the rationale for each medication, they are less likely to inadvertently duplicate prescriptions, send mixed messages, or reinforce maladaptive expectations. For example, if everyone involved agrees that benzodiazepines are reserved only for rare, clearly defined emergencies, emergency department providers are less likely to administer them reflexively for every functional seizure. Shared treatment plans—summarized in letters or electronic records—help ensure that medication decisions support, rather than undermine, the broader rehabilitative agenda.
Regular, planned medication reviews offer a structured opportunity to identify and correct emerging problems before they become entrenched. These reviews can focus on questions such as: Which medications are clearly helping, based on agreed‑upon indicators? Which ones have unclear benefit or significant side effects? Are there agents that were started for short‑term reasons but never revisited? Could doses be reduced without loss of benefit, or could some drugs be tapered off entirely as function improves? By routinely asking these questions in partnership with the patient, clinicians send a powerful message that medication is dynamic, revisable, and always subordinate to the overarching goal of restoring autonomy, activity, and quality of life.
Collaborative care: integrating medications with rehabilitation and psychotherapy
Effective treatment relies on viewing pharmacologic strategies, physical rehabilitation, and psychotherapy as interlocking components of a single plan rather than as separate or competing approaches. Medication is positioned as a tool to reduce barriers—such as overwhelming anxiety, depression, pain, or insomnia—that prevent full participation in therapy and daily activities. Physiotherapists, psychologists, occupational therapists, and prescribing clinicians work from a shared formulation that explains how symptoms developed and what keeps them going, so that every element of care, including each prescription, points in the same direction: greater confidence, self‑efficacy, and functional independence.
Clear, consistent messaging across the team is central to this integration. If a neurologist frames functional seizures as a reversible brain network problem best addressed through education and behavioral change, while a psychiatrist emphasizes long‑term pharmacologic management of “severe illness,” or a therapist avoids discussion of medication altogether, patients receive confusing and sometimes contradictory narratives. Instead, all clinicians should use similar language, explicitly acknowledging that medications such as an SSRI or SNRI may ease mood or arousal, but that the core retraining of attention, movement, and threat responses happens through practice and learning in rehabilitation and psychotherapy. Written summaries or shared care plans given to the patient and circulated among providers help maintain this unified approach.
Shared goal‑setting is a practical way to connect medication decisions with the work done in therapy and rehabilitation. Rather than defining success solely as symptom reduction, the team collaborates with the patient to identify specific functional goals: walking to the local store independently, returning to a few hours of work each week, resuming hobbies, or tolerating social situations that previously triggered episodes. When a new medication is considered, its purpose is articulated in terms of how it might support these goals—for example, “We are trying this antidepressant to reduce the background anxiety that makes physiotherapy more frightening,” or “This low‑dose sedating antidepressant is intended to improve sleep so you have more energy to practice the techniques from therapy.” Progress toward these goals then becomes a key indicator of whether the medication is genuinely helping.
Close coordination between prescribers and rehabilitation clinicians is crucial when planning the timing and dosing of medications. Sedating agents can interfere with physiotherapy sessions if taken shortly beforehand, increasing fall risk and blunting the alertness needed for motor relearning. Similarly, changes in medication—such as starting an SSRI, tapering benzodiazepines, or reducing analgesics—can temporarily alter energy, mood, or physical sensations, which may influence performance in therapy. Proactive communication about medication changes allows therapists to anticipate transient effects, adjust session timing or intensity, and help patients interpret new sensations without catastrophizing them as relapse or deterioration.
Psychotherapists and physiotherapists also play a key role in monitoring both benefits and side effects. Because they often see patients more frequently and in more active contexts than prescribing clinicians, they may detect patterns that are not obvious in brief medical appointments—for example, increased dissociation after dose escalations, greater daytime sleepiness interfering with sessions, or improved participation coinciding with stable medication use. Therapists can feed these observations back to prescribers, enriching the information base for decisions about dose adjustments or deprescribing. At the same time, they can help patients understand normal fluctuations and avoid attributing every change in symptoms to medication, reinforcing the principle that behavior and practice remain central.
Integrating psychotherapy with pharmacologic treatment requires thoughtful sequencing and transparent discussion of the rationale. For some individuals, severe depression, suicidality, or extreme hyperarousal may need partial stabilization with medication before in‑depth trauma‑focused work or intensive exposure‑based physiotherapy is feasible. In such cases, the plan is shared explicitly: medications create a “window of tolerance” within which psychological and physical therapies can proceed more safely and effectively. For others, starting therapy and rehabilitation early, with medication as a later adjunct if needed, may be appropriate. Decisions about timing are individualized but always framed so that medication and therapy are partners, not alternatives.
Many psychotherapeutic techniques used in FND—such as cognitive‑behavioral therapy, psychodynamic therapy, trauma‑focused approaches, or third‑wave models like acceptance and commitment therapy—work best when patients can access and reflect on internal states without excessive sedation or cognitive blunting. Overuse of benzodiazepines or other centrally sedating drugs can dull affect, impair memory for sessions, and reduce the discomfort necessary for exposure and emotional processing to be effective. When such medications are already in place, therapists and prescribers collaborate on gradual dose reductions, timed in a way that does not destabilize the patient but steadily increases their capacity to engage actively in treatment.
Rehabilitation professionals often serve as “translators” of the medical plan into everyday behavior. For example, a physiotherapist might help a person notice how reduced panic attacks after starting an SSRI make it easier to attempt new movements or tolerate public environments that previously triggered functional seizures. By explicitly linking these experiential gains to both medication and the person’s own efforts, the therapist reinforces a balanced attribution: the drug lowered a barrier, but the patient’s practice and persistence produced the functional change. This framing prevents an overreliance on pharmacology and underlines that the central driver of progress is learned change, not passive receipt of treatment.
Occupational therapists contribute by integrating medication schedules and anticipated effects into daily routines and graded activity plans. They may suggest, for instance, that more demanding cognitive tasks be scheduled at times of day when sedative effects are lowest, or that rest breaks be planned around periods when pain is expected to flare as analgesics wear off. They can also help patients track correlations between medication timing, activity level, and symptom patterns, distinguishing predictable, manageable side effects from signs that a regimen needs adjustment. These practical strategies make the medication regimen more compatible with real‑world functioning and support adherence without sacrificing engagement in rehabilitation.
From the outset, the team should discuss with the patient how evidence from psychiatric, pain, and rehabilitation research informs the overall approach, while acknowledging that the specific evidence base for pharmacologic treatment in FND is still evolving. Explaining that medications are used where there is reasonable indirect evidence of benefit—for example, using an SSRI for comorbid depression shown to worsen functional symptoms—helps demystify prescribing and counters fears that drugs are being used experimentally or as a substitute for “real” treatment. Equally important is reinforcing that the strongest evidence for durable improvement in FND comes from education, focused physiotherapy, and psychologically informed interventions, making it clear why so much emphasis is placed on these modalities.
Regular multidisciplinary case reviews provide a structured forum to align strategies and adjust the integrated plan as circumstances change. In these meetings, the team examines which medications are clearly supporting participation in therapy, which may be causing problematic side effects or reinforcing avoidance, and whether the balance between pharmacologic and non‑pharmacologic interventions remains appropriate. If, for example, a person remains heavily reliant on crisis doses of benzodiazepines despite months of therapy, the team might shift focus toward intensive coping‑skills training, tighter prescribing boundaries, or exploring unaddressed trauma. If rehabilitation gains plateau while mood remains fragile, a cautious adjustment of antidepressant dose may be considered alongside modifications to therapy intensity or style.
Patients and families benefit from being included in these collaborative processes as much as possible. Inviting them to multidisciplinary appointments, joint feedback sessions, or teleconferences allows them to hear the consistent message that all team members view recovery as feasible and understand the distinct but complementary roles of each treatment. Families who have witnessed dramatic but short‑lived responses to medications in emergency settings may initially expect pharmacologic “fixes”; hearing a united explanation of why long‑term reliance on such approaches is risky and how rehabilitation and psychotherapy offer more stable gains can recalibrate expectations. Providing written summaries of agreed plans reduces confusion and prevents fragmented, provider‑specific narratives from taking hold.
Throughout this collaborative care process, the team maintains an active stance toward reviewing and revising medication use as functional goals are met. As patients gain skills, confidence, and resilience through therapy and rehabilitation, the need for certain medications often diminishes. Tapering becomes a shared project, paced to protect mood and sleep while emphasizing the person’s growing capacity to manage symptoms using non‑pharmacologic tools. Each successful reduction reinforces the central message of integrated care: medications can be valuable allies, but long‑term change in functional neurological disorder is built primarily through understanding, practice, and participation in life, supported by a coordinated team working toward the same aims.
